171 related articles for article (PubMed ID: 122683)
1. Penicillamine therapy in systemic sclerosis.
Jayson MI; Lovell C; Black CM; Wilson RS
Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):82-8. PubMed ID: 122683
[TBL] [Abstract][Full Text] [Related]
2. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial.
Rook AH; Freundlich B; Jegasothy BV; Perez MI; Barr WG; Jimenez SA; Rietschel RL; Wintroub B; Kahaleh MB; Varga J
Arch Dermatol; 1992 Mar; 128(3):337-46. PubMed ID: 1550365
[TBL] [Abstract][Full Text] [Related]
3. Progressive systemic sclerosis and penicillamine.
Rodnan GP
J Rheumatol Suppl; 1981; 7():116-20. PubMed ID: 6939873
[TBL] [Abstract][Full Text] [Related]
4. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine [see comment].
Jimenez SA; Sigal SH
J Rheumatol; 1991 Oct; 18(10):1496-503. PubMed ID: 1765974
[TBL] [Abstract][Full Text] [Related]
5. D-penicillamine treatment of progressive systemic sclerosis (scleroderma): a comparison of clinical and in vitro effects.
Shapiro LS; Prince RK; Buckingham RB; Rodnan GP
J Rheumatol; 1983 Apr; 10(2):316-8. PubMed ID: 6864687
[TBL] [Abstract][Full Text] [Related]
6. [Systemic sclerosis].
Gustafsson R
Nord Med; 1994; 109(8-9):236-7. PubMed ID: 7937033
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of systemic scleroderma with D-penicillamine. Results in 14 patients treated for more than a year].
Kahn MF; Bourgeois P; Brion N; Elleuch M
Rev Rhum Mal Osteoartic; 1986 Jan; 53(1):35-8. PubMed ID: 3704510
[TBL] [Abstract][Full Text] [Related]
8. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
[TBL] [Abstract][Full Text] [Related]
9. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
[TBL] [Abstract][Full Text] [Related]
10. Treatment of systemic sclerosis.
Medsger TA
Rheum Dis Clin North Am; 1989 Aug; 15(3):513-31. PubMed ID: 2672135
[TBL] [Abstract][Full Text] [Related]
11. Treatment of generalized scleroderma with inhibitors of connective tissue formation.
Asboe-Hansen G
Acta Derm Venereol; 1975; 55(6):461-5. PubMed ID: 55038
[TBL] [Abstract][Full Text] [Related]
12. [D-penicillamine in the treatment of progressive systemic sclerosis].
Marques Neto JF; Manzato LC; Samara AM
AMB Rev Assoc Med Bras; 1980 Jun; 26(6):191-3. PubMed ID: 6970374
[No Abstract] [Full Text] [Related]
13. [Treatment of interstitial pulmonary fibrosis with D-penicillamine in progressive scleroderma: a long-term study (author's transl)].
Bröll H; Tausch G; Eberl R
Wien Klin Wochenschr; 1976 Apr; 88(9):292-5. PubMed ID: 973388
[TBL] [Abstract][Full Text] [Related]
14. [Minimal changes nephrotic syndrome associated to penicillamine treatment].
Basterrechea MA; de Arriba G; García-Martín F; Sánchez-Heras M; Giménez-Vega E; Sánchez J
Nefrologia; 2004; 24(2):183-7. PubMed ID: 15219094
[TBL] [Abstract][Full Text] [Related]
15. [Renal scleroderma crisis. Role of scleroderma vasculopathy in the induction of cutaneous and visceral fibrosis in 2 cases].
Cuchacovich M; Holuigue G; Gatica H; Alvo M; Murray G
Rev Med Chil; 2000 Jan; 128(1):86-92. PubMed ID: 10883527
[TBL] [Abstract][Full Text] [Related]
16. D-penicillamine induced crescentic glomerulonephritis: report and review of the literature.
Devogelaer JP; Pirson Y; Vandenbroucke JM; Cosyns JP; Brichard S; Nagant de Deuxchaisnes C
J Rheumatol; 1987 Oct; 14(5):1036-41. PubMed ID: 3430507
[TBL] [Abstract][Full Text] [Related]
17. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin R; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold J
Arthritis Rheum; 1999 Nov; 42(11):2372-80. PubMed ID: 10555033
[TBL] [Abstract][Full Text] [Related]
18. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
Clements PJ; Hurwitz EL; Wong WK; Seibold JR; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Furst DE
Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267
[TBL] [Abstract][Full Text] [Related]
19. Does long-term treatment with D-penicillamine alter calcium and phosphorus metabolism in patients with systemic sclerosis?
Hagdrup H; Serup J; Tvedegaard E
Acta Derm Venereol; 1983; 63(5):447-9. PubMed ID: 6197850
[TBL] [Abstract][Full Text] [Related]
20. Treatment of systemic sclerosis.
Wigley FM
Curr Opin Rheumatol; 1992 Dec; 4(6):878-86. PubMed ID: 1457284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
